tetano
Editor, Senior Moderator
- Allan De Clercq[SUP]1,2[/SUP] , François Blanquart[SUP]3[/SUP] , Vincent Vieillefond[SUP]4[/SUP] , Benoit Visseaux[SUP]5[/SUP] , Alexandra Jacques[SUP]6[/SUP] , Stéphanie Haim-Boukobza[SUP]7[/SUP] , Valentin Wehrle[SUP]8[/SUP] , Guillaume Deleglise[SUP]9[/SUP] , Thomas Duret[SUP]9[/SUP] , Sibylle Bernard-Stoecklin[SUP]10[/SUP] , Danielle Perez-Bercoff[SUP]11[/SUP] , Antoine Oblette[SUP]1,12[/SUP] , Bruno Lina[SUP]1,12[/SUP] , Marie Anne Rameix-Welti[SUP]11,13[/SUP] , Laurence Josset[SUP]1,12[/SUP] , Vincent Enouf[SUP]11[/SUP] , Antonin Bal[SUP]1,12[/SUP] , on behalf of the RELAB study group[SUP]14[/SUP]
In Europe, the 2025/26 seasonal influenza epidemic started in October 2025. Co-circulation of A(H3N2) and A(H1N1)pdm09 was observed in several countries including France. We estimated early vaccine effectiveness (VE) against influenza virus in French outpatients (5,451 positives/18,816 negatives). A significant VE across all age groups was measured: 28% (95% CI: 17–37) for those aged ≥ 65 years, 45% (95% CI: 36–53) for 18–64-year-olds and 57% (95% CIs: 29–74) for 0–17-year-olds. Reinforcing vaccination uptake is warranted.
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2026.31.2.2500992#html_fulltext